Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.

JCO Global Oncology
Vishwanath SathyanarayananSwaminathan P Iyer

Abstract

This review will compare and contrast the costs and access to novel drugs for treating chronic lymphocytic leukemia (CLL) and lymphoma in the United States and India during the last 5 years. Clinical outcomes for patients with hematologic malignancies have improved significantly since the approval of immunotherapeutic and targeted therapies. These new treatments have had an impact on overall outcomes and have helped determine the design for translational research and future trials. Although most of these novel drugs called "innovators" are initially approved and marketed in the United States, several have also become available in countries such as India. With the expiration of patents, generic versions of innovator drugs have increased and accessibility has improved for patients. The advent of biosimilars is another route for expanding access to biologic compounds. As a result, the development costs for developing these drugs are lower, and consequently, the costs for the patient are often lower. Although the delivery of cancer care is not the same in India as it is in the United States, the introduction of biosimilars and generics has helped bridge the gap. This has made treatment of CLL and lymphoma similar in both countries ...Continue Reading

References

Dec 17, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoyR I Fisher
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nathalie A JohnsonRandy D Gascoyne
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jul 5, 2013·Bulletin of the World Health Organization·Dianne Nicol, Olasupo Owoeye
Sep 5, 2013·Cancer·Donald W Light, Hagop Kantarjian
Dec 25, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stacie B DusetzinaNancy L Keating
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
Jul 1, 2012·South Asian Journal of Cancer·Vanita NoronhaKumar Prabhash
Jan 30, 2014·Cancer·Xuesong HanElizabeth Ward
Feb 5, 2014·JAMA Internal Medicine·Aarti Kakkar, Brian C Jacobson
Mar 8, 2014·Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology·Partha Sarathi RoyReena Nair
May 8, 2014·Journal of Oncology Practice·Hagop KantarjianDonald Light
Jun 20, 2014·British Journal of Haematology·Yasuhiro OkiJason R Westin
Sep 19, 2014·World Journal of Gastrointestinal Oncology·Ambedkar Raj Kulandai VeluIlavarasi Sinduja
Mar 5, 2015·The New England Journal of Medicine·Tadeusz RobakUNKNOWN LYM-3002 Investigators
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardBruce D Cheson
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Jan 31, 2016·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Theresa H M KeeganSally L Glaser
Jun 23, 2016·Cancer Chemotherapy and Pharmacology·Vikram GotaHari Menon
Jul 12, 2016·JAMA : the Journal of the American Medical Association·Barack Obama
Aug 9, 2016·Cancer·Michael T Halpern, Otis W Brawley
Apr 21, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine ThieblemontBertrand Coiffier
Apr 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert ChenUNKNOWN KEYNOTE-087
Jul 19, 2017·Journal of Global Oncology·Cinthia Leite Frizzera Borges BognarGilberto de Lima Lopes
Oct 5, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin DreylingPier Luigi Zinzani
Oct 5, 2017·The New England Journal of Medicine·Robert MarcusWolfgang Hiddemann
Dec 12, 2017·The New England Journal of Medicine·Joseph M ConnorsUNKNOWN ECHELON-1 Study Group
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go
Mar 15, 2018·JAMA : the Journal of the American Medical Association·Irene PapanicolasAshish K Jha
Mar 22, 2018·The New England Journal of Medicine·John F SeymourArnon P Kater

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01728805
NCT02576990
NCT02257567
NCT01712490
NCT01777152
NCT01886872
NCT01722487
NCT02213926
NCT02970318
NCT02475681

Software Mentioned

Reditux

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.